Latest News

Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.
HER2-Related Biomarkers Confer Response to T-DXd in Advanced Gastric Cancer

May 22nd 2024

Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.

Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.
FDA Withdraws Infigratinib Approval Status in FGFR2+ Cholangiocarcinoma

May 20th 2024

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.
Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST

May 9th 2024

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
FDA Approves Noninvasive Stool RNA Test for Colorectal Cancer Screening

May 7th 2024

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.
Nivolumab/Ipilimumab Receive Type II Validation by EMA in MSI-H/dMMR mCRC

May 6th 2024

More News